Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis
| Autor: | Atul Malhotra, Najib T. Ayas, Jay H. Ryu, Michael Schulzer, Edwin Mak, Ednan K. Bajwa |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry Respiratory disease Hazard ratio Context (language use) Critical Care and Intensive Care Medicine medicine.disease Confidence interval law.invention Surgery Idiopathic pulmonary fibrosis Randomized controlled trial law Internal medicine Meta-analysis Pulmonary fibrosis medicine Cardiology and Cardiovascular Medicine business |
| Zdroj: | Chest. 128:203-206 |
| ISSN: | 0012-3692 |
| DOI: | 10.1378/chest.128.1.203 |
| Popis: | Context Despite the investigation of multiple therapeutic options, idiopathic pulmonary fibrosis (IPF) remains a devastating, progressively fatal disease. Much interest has focused on the use of interferon (IFN)-γ1b therapy, but the efficacy of this treatment has not been proven. Objective To determine whether IFN treatment reduces mortality in patients with IPF. Design A metaanalysis of randomized controlled trials evaluating the use of IFN-γ1b as treatment for IPF. Main outcome measure Mortality in patients treated with IFN-γ1b was compared to mortality in patients treated with control therapies. Results A total of three studies involving 390 patients was included in the analysis. IFN-γ1b therapy was associated with reduced mortality (hazard ratio [HR], 0.418; 95% confidence interval [CI], 0.253 to 0.690; p = 0.0003). A comparison of mortality at different time points revealed that IFN-γ1b therapy was associated with significantly reduced mortality at 1 year (0.0861; 95% CI, 0.0244 to 0.1478; p = 0.0063), 18 months (0.1682; 95% CI, 0.1065 to 0.2299; p Conclusion When the results of multiple studies are combined in a metaanalysis, IFN-γ1b therapy is associated with reduced mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|